Opinion|Videos|September 4, 2024
Safety and Efficacy of GnRHa Treatments in Central Precocious Puberty
The panel examines the efficacy and safety profiles of gonadotropin-releasing hormone analogue (GnRHa) treatments in managing Central Precocious Puberty.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are long-term efficacy and safety data associated with gonadotropin releasing hormone analogue (GnRHa) treatment?
Advertisement
Related to this article
Nationwide Children's experts urge early screening and family-based lifestyle change as youth-onset T2D progresses faster than adult disease.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
ISPAD, EASD, and ADA urge pediatric diabetes teams to build center-specific transition policies, use readiness checklists, and ensure timely handoffs to adult clinicians.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Hand, foot, and mouth disease: Red flags pediatricians should know
2
FDA approval of Gazyva offers new option for pediatric INS
3
DTaP 96% effective against pertussis in Alaska outbreak
4
FDA grants Cinainu Breakthrough Therapy status for pediatric AA
5